Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells

Glucagon-Like Peptide (GLP)-1(9-36)Amide-Mediated Cytoprotection Is Blocked by Exendin(9-39) Yet Does Not Require the Known GLP-1 Receptor

(2010) Kiwon Ban et al.   ENDOCRINOLOGY

Nitric oxide – the endothelium-derived relaxing factor and its role in endothelial functions

(2010) V. Bauer et al.   GENERAL PHYSIOLOGY AND BIOPHYSICS

Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP

(2009) Rolf Mentlein   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression

(2009) Yuji Ishibashi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo

(2009) David Nathanson et al.   REGULATORY PEPTIDES

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

(2008) Kiwon Ban et al.   CIRCULATION

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

(2008) P. V. Højberg et al.   DIABETOLOGIA